Breast Cancer Clinical Trial
Official title:
A Phase II Trial of Endocrine Therapy in Combination With OSI-906 (an IGF-1R Inhibitor) With or Without Erlotinib (Tarceva, an EGFR Inhibitor) in Patients With Hormone-sensitive Metastatic Breast Cancer.
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using
letrozole +/- goserelin (the latter for pre-menopausal women only) may fight breast cancer
by lowering the amount of estrogen the body makes. OSI-906 and erlotinib hydrochloride may
stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is
not yet known whether hormone therapy and OSI-906 are more effective when given with or
without erlotinib hydrochloride in treating hormone-sensitive metastatic breast cancer.
PURPOSE: This phase II trial is studying how well giving hormone therapy together with
OSI-906 with or without erlotinib hydrochloride works in treating hormone-sensitive patients
with metastatic breast cancer.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | December 2009 |
Est. primary completion date | December 2009 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
DISEASE CHARACTERISTICS: - Histologically confirmed invasive breast carcinoma - Stage IV disease - No locally recurrent resectable disease - No symptomatic brain metastases - History of brain metastases allowed provided the patient is clinically stable for > 3 weeks after completion of radiotherapy AND is not taking steroids or therapeutic anticonvulsants that are CYP3A4 modifiers - Hormone receptor status: - Estrogen receptor and/or progesterone receptor positive tumor by immunohistochemistry (IHC) PATIENT CHARACTERISTICS: - Pre- or post-menopausal - ECOG performance status 0-1 - Life expectancy = 6 months - ANC = 1,250/mm^3 - Platelet count = 100,000/mm^3 - Creatinine = 1.5 times upper limit of normal (ULN) - Bilirubin = 1.5 times ULN (= 3 times ULN if liver metastasis is present) - For patients with Gilbert syndrome, direct bilirubin will be measured instead of total bilirubin - SGOT and SGPT = 1.5 times ULN (= 3 times ULN if liver metastasis is present) - Alkaline phosphatase = 1.5 times ULN (= 3 times ULN if liver metastasis is present) - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective barrier contraception during and for 3 months after completion of study therapy - Able to swallow and retain oral medication - Baseline QTc = 450 msec - No other invasive cancer within the past 5 years except for completely resected basal cell or squamous cell skin cancer or successfully treated cervical carcinoma in situ - No malabsorption syndrome significantly affecting gastrointestinal function - No diabetes, fasting glucose > 150mg/dL, or receiving ongoing anti-hyperglycemic therapies - No concurrent uncontrolled illness including, but not limited to, any of the following: - Ongoing or active infection requiring parenteral antibiotics - Impaired lung function (i.e., COPD or lung conditions requiring oxygen therapy) - Symptomatic congestive heart failure (NYHA class III or IV heart disease) - Unstable angina pectoris, angioplasty, stenting, or myocardial infarction within the past 6 months - Uncontrolled hypertension, defined as systolic BP > 180 mm Hg or diastolic BP > 100 mm Hg on two consecutive measurements taken = 1 week apart, despite adequate medical support - Clinically significant cardiac arrhythmia (multifocal premature ventricular contractions, bigeminy, trigeminy, or ventricular tachycardia that is symptomatic or requires treatment) - Psychiatric illness and/or social situation that would compromise patient safety or limit compliance with study requirements, including maintenance of a compliance/pill diary PRIOR CONCURRENT THERAPY: - See Disease Characteristics - Recovered from prior therapy - At least 2 weeks since prior investigational drugs - No more than 4 prior chemotherapy treatments in the metastatic setting - Does not include endocrine therapy or single-agent biologic therapy - No concurrent CYP3A4 or CYP1A2 modifiers - No other concurrent anticancer therapy, including chemotherapy, radiotherapy, surgery, immunotherapy, hormonal therapy, or biologic therapy - Concurrent radiotherapy to painful bone metastases or areas of impeding bone fracture allowed provided radiotherapy is initiated before study therapy |
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Vanderbilt-Ingram Cancer Center | National Cancer Institute (NCI) |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Time to progression | Duration from study enrollment to date of progressive disease (PD) as measured by Response Evaluation in Solid Tumors (RECIST) criteria v. 1.1: measurable lesions: PD is > 20% increase in the sum of the longest diameter of target lesions or appearance of new lesions | from study entry to date of progressive disease | No |
Secondary | Safety profile of OSI-906 and letrozole +/ goserelin, with and without erlotinib | The number of patients with worst-grade toxicity at each of five grades following NCI Common Toxicity Criteria: 1 = mild, 2 = moderate, 3 = severe, 4 = life-threatening, disabling, 5 = death | at 4 weeks | Yes |
Secondary | Response | Per RECIST criteria v. 1.1: measurable lesions: complete response (CR) disappearance of target lesions, partial response (PR) > 30% decrease in the sum of the longest diameter (LD) of target lesions, progressive disease (PD) > 20% increase in the sum of the LD of target lesions or appearance of new lesions, stable disease (SD) neither sufficient decrease nor increase of the sum of smallest sum of the LD of target lesions | every 12 weeks to progression | No |
Secondary | Circulating C-peptide, IGF-1 | Levels of the protein C-peptide and the hormone IGF-1 in the blood | At baseline and on day 1 of each 28-day cycle | No |
Secondary | Correlation of IGF-IR, EGFR, HER2, Y1316 and Y1131 pIGF-1R, PTEN, S473 pAkt, pMAPK, S118 (MAPK site), and S167 (Akt and S6 site) pER expression with time to progression and molecular classification | The levels of these biomarkers will be measured in breast tumor tissue and compared and contrasted with patient's time to progression and molecular classification (luminal A vs. luminal B) | On receipt of breast tissue: tissue block from prevous surgery or fresh tissue from current surgery | No |
Secondary | Mutation analysis of PI3K (E542K, E545K, H1047R) | Breast tumor tissue will be examined for mutations in these genes. | On receipt of breast tissue: tissue block from prevous surgery or fresh tissue from current surgery | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A |